Should You Ignore Rocket Lab Stock? Why SpaceX May Be the Better Space Stock Today.

Rocket Lab (RKLB) shares fell back to just over $64 after trading from under $65 at end-July to above $86 mid-month, as investors appeared to rotate toward SpaceX (SPCX), with SPCX up 30% in August. Despite Rocket Lab’s operational momentum (93rd Electron launch on Aug. 20; 14 launches YTD) and new U.S. Space Force awards ($12M for SDN-B and a drafted role in a $981M NITE-STAR program), the article argues SpaceX’s superior tech and launch cadence—e.g., Starship test-flight progress and scale targets—keeps Rocket Lab from being the next SpaceX. The key fundamental offset is Rocket Lab’s $8B Iridium (IRDM) acquisition in June (aiming for GAAP profitability and free-cash-flow positive next year), but sentiment remains cautious.

Analysis

The market is treating this less like a launch-services story and more like a credibility trade: the public market is discounting any "next SpaceX" narrative until Rocket Lab proves it can close the product gap without repeated schedule slippage. That matters because in this category, valuation is driven less by revenue growth than by the probability-weighted path to operating leverage; every quarter of delay keeps RKLB trapped in a lower multiple regime while the category leader compounds a much wider moat.

The Iridium deal is the key second-order lever. It can improve near-term cash generation optics, but it also raises integration risk and increases the odds that future upside gets diluted by financing or stock-based consideration; if the market starts to price in deal complexity rather than synergies, the transaction becomes a valuation overhang instead of a catalyst. Meanwhile, SpaceX's multi-product platform reduces the addressable upside for smaller launch pure-plays and pressures satellite-comms incumbents by making vertical integration a defensive necessity.

Near term, the cleanest catalyst is not another contract award but any sign that Neutron slips again or that management must guide around launch timing to defend the profitability bridge. Over 6-18 months, the thesis flips only if RKLB demonstrates on-time Neutron progress and converts the Iridium asset into verifiable FCF without incremental dilution. The contrarian view is that the selloff may be a bit too reflexive if the market is underestimating how quickly a profitable, cash-generative RKLB could rerate once execution risk starts to fade; the key is that this rerating is binary and needs hard proof, not narrative.

Key Decisions for Investors

• Short RKLB on strength for a 1-3 month trade; use a stop above the post-rally range and cover into any Neutron launch-date confirmation. Risk/reward is attractive because the downside is driven by schedule skepticism, while upside requires a credible execution milestone.
• Long IRDM only as a merger-spread / event-driven position, not as a standalone growth long; size it as a closing-risk trade and re-underwrite if financing terms worsen. The spread should compress if the market believes the acquisition meaningfully de-risks RKLB's free-cash-flow path.
• Pair trade: long SPCX / short RKLB for relative-value exposure to the "best-in-class" premium. This expresses the idea that the market will continue to reward the leader's compounding economics while penalizing the challenger until hardware execution is proven.
• Set an alert on RKLB around the next guidance update and Neutron milestone; if management narrows launch timing and preserves FCF targets without dilution, cover shorts quickly. If guidance slips again, expect another multiple reset over the following 2-6 weeks.